Protein and Drug Biochemistry

Publications

  • Crehan H, Liu B, Kleinschmidt M, Rahfeld J-U, Le KX, Caldarone BJ, Frost JL, Hettmann T, Hutter-Paier B, O'Nuallain B, Park M-A, DiCarli MF, Lues I, Schilling S, Lemere CA. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's like mice. Alzheimer's research & therapy 12 (2020) Artikelnr.: 12 (2020), 19 Seiten. dx.doi.org/10.1186/s13195-019-0579-8
  • Gnoth K, Piechotta A, Kleinschmidt M, Konrath S, Schenk M, Taudte N, Ramsbeck D, Nykiel V, Geißler S, Eichentopf R, Barendrecht S, Hartlage-Rübsamen M, Demuth H-U, Roßner S, Cynis H, Rahfeld J-U, Schilling S. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology. Alzheimer's research & therapy 12 (2020) Artikel-Nr.: 149, 20 Seiten. dx.doi.org/10.1186/s13195-020-00719-x
  • Hettmann T, Gillies SD, Kleinschmidt M, Piechotta A, Makioka K, Lemere CA, Schilling S, Rahfeld J-U, Lues I. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specifc antibody against Alzheimer's disease with reduced complement activation. Scientific reports 10 (2020) Artikel-Nr.: 3294, 13 Seiten. dx.doi.org/10.1038/s41598-020-60319-5
  • Köppen J, Schulze A, Machner L, Wermann M, Eichentopf R, Guthardt M, Hähnel A, Klehm J, Kriegeskorte M-C, Hartlage-Rübsamen M, Morawski M, Hörsten S von, Demuth H-U, Roßner S, Schilling S. Amyloid-beta peptides trigger aggregation of alpha-synuclein in vitro. Molecules Volume 25 (2020) Issue 3, 18 Seiten. dx.doi.org/10.3390/molecules25030580
  • Kupski O, Funk L-M, Sautner V, Seifert F, Worbs B, Ramsbeck D, Meyer F, Diederichsen U, Buchholz M, Schilling S, Demuth H-U, Tittmann K. Hydrazides are potent transition-state analogues for glutaminyl cyclase implicated in the pathogenesis of Alzheimer's disease. Biochemistry 59 (2020) 28, Seite 2585-2591. dx.doi.org/10.1021/acs.biochem.0c00337
  • Monasor LS, Müller SA, Colombo AV, Tanrioever G, König J, Roth S, Liesz A, Berghofer A, Piechotta A, Prestel M, Saito T, Saido TC, Herms J,Willem M, Haass C, Lichtenthaler SF, Tahirovic S. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. eLife 9 (2020) Artikel-Nr.: 54083, 33 Seiten. dx.doi.org/10.7554/eLife.54083
  • Uhlmann RE, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes EM, Fritschi SK, Buehler A, Baumann F, Skodras A, Al Shaana R, Beschorner N, Ye L, Kaeser SA, Obermüller U, Christensen S, Kartberg F, Stavenhagen JB, Rahfeld JU, Cynis H, Qian F, Weinreb PH, Bussiere T, Walker LC, Staufenbiel M, Jucker M. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nature Neuroscience 23 (2020), Seite 1580–1588. dx.doi.org/10.1038/s41593-020-00737-w
  • Hartlage-Rübsamen M, Ratz V, Zeitschel U, Finzel L, Machner L, Köppen J, Schulze A, Demuth HU, von Hörsten S, Höfling C, Rossner S. Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, coaggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer’s disease. Acta Neuropathologica Communications, (2019) 7:79
  • Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, Rossner S. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease. Acta Neuropathologica 2015; 129(4): 565-583. DOI dx.doi.org/10.1007/s00401-015-1395-2
  • Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, Roßner S. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer‘s disease. Journal of Alzheimer‘s Disease. 2014;39(2):385-400. DOI dx.doi.org/10.3233/JAD-131535.
  • Güttler BH, Cynis H, Seifert F, Ludwig HH, Porzel A, Schilling S. A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues. 2013 Apr;44(4):1205-14. DOI dx.doi.org/10.1007/s00726-012-1454-0. Epub 2013 Jan 24.
  • Nussbaum JM*, Schilling S*, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-?. Nature. 2012 May 2;485(7400):651-5. DOI dx.doi.org/10.1038/nature11060
  • Schilling S, Kohlmann S, Bäuscher C, Sedlmeier R, Koch B, Eichentopf R, Becker A, Cynis H, Hoffmann T, Berg S, Freyse EJ, von Hörsten S, Rossner S, Graubner S, Demuth HU. Glutaminyl cyclase (QC) knock out mice show mild hypothyreodism but absence of hypogonadism: implications for enzyme function and drug development. J Biol Chem. 2011 Apr 22;286(16):14199-208. DOI dx.doi.org/10.1074/jbc.M111.229385
  • Seifert F, Schulz K, Koch B, Manhart S, Demuth HU, Schilling S. Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates. Biochemistry. 2009 Dec 22;48(50):11831-3. DOI dx.doi.org10.1021/bi9018835
  • Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med. 2008 Oct;14(10):1106-11. DOI dx.doi.org/10.1038/nm.1872